AbbVie Stock (NYSE:ABBV)
Previous Close
$234.89
52W Range
$181.73 - $244.81
50D Avg
$213.88
200D Avg
$221.05
Market Cap
$429.58B
Avg Vol (3M)
$6.25M
Beta
0.31
Div Yield
$6.74 (2.77%)
ABBV Company Profile
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
ABBV Performance
Revenue Breakdown
Revenue Breakdown by Product/Service
| Product/Service | Dec 25 | Dec 24 | Dec 23 |
|---|---|---|---|
| Qulipta | $1.04B | $658.00M | $408.00M |
| Other Products | $2.63B | $3.03B | $3.04B |
| MAVYRET | $1.32B | $1.31B | $1.43B |
| Linzess/Constella | $907.00M | $954.00M | $1.11B |
| VENCLEXTA | $2.79B | $2.58B | $2.29B |
| Imbruvica | $2.87B | $3.35B | $3.60B |
| Vraylar | $3.62B | $3.27B | $2.76B |
| Ubrelvy | $1.27B | $1.01B | $815.00M |
| Other Neuroscience | $207.00M | $338.00M | $276.00M |
| Duodopa | $381.00M | $447.00M | $468.00M |
| Botox Therapeutic | $3.77B | $3.28B | $2.99B |
| SKYRIZI | $17.56B | $11.72B | $7.76B |
| RINVOQ | $8.30B | $5.97B | $3.97B |
| H U M I R A | $4.54B | $8.99B | $14.40B |
| Ozurdex | $493.00M | $494.00M | $472.00M |
| Other Eye Care | $1.01B | $847.00M | $803.00M |
| Lumigan/Ganfort | $410.00M | $429.00M | $432.00M |
| Alphagan/Combigan | $197.00M | $248.00M | $272.00M |
| Other Aesthetics | $1.26B | $1.28B | $1.23B |
| Juvederm Collection | $993.00M | $1.18B | $1.38B |
| Botox Cosmetic | $2.60B | $2.72B | $2.68B |
| Restasis | - | $224.00M | $436.00M |
Fiscal year ends in Dec 25 | Currency in USD